Literature DB >> 1971459

Neurologic approach to drug-induced movement disorders: a study of 125 patients.

L G Miller1, J Jankovic.   

Abstract

Of 125 patients with neuroleptic (dopamine blocking) drug-induced movement disorders who had been referred to a specialized clinic to differentiate the predominant movement disorder, 63% had tardive dyskinesia, 30% had parkinsonism, 24% had dystonia, 7% had akathisia, and 2% had isolated tremor. Two or more movement disorders coexisted in 31 patients (25%). Functional disability was more severe in patients with akathisia than in other patients. Women outnumbered men at a ratio of 4:1, except for tardive dystonia which affected both sexes equally. The average at onset was 56 years (range, 13 to 87); 69 patients (55%) had onset of movement disorder in the sixth decade. While tardive dystonia was distributed relatively evenly in all age groups, almost a third of patients with parkinsonism had it in the eighth decade. Haloperidol was implicated in 47 patients (37%), followed by amitriptyline/perphenazine in 30%, thioridazine in 27%, and chlorpromazine in 20%. Metoclopramide-induced movement disorders were found in 10 (8%). Most patients (101 or 81%) had history of psychiatric illnesses, but of these only 44 had psychosis. Neuroleptic drugs had been prescribed for 33 patients (26%) who had gastrointestinal problems. It is important to recognize and differentiate various drug-induced movement disorders because such differentiation has pathophysiologic and therapeutic implications. Many patients could have been treated with less potent drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971459     DOI: 10.1097/00007611-199005000-00011

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  9 in total

1.  Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.

Authors:  Jose J Mateos; Francisco Lomeña; Eduard Parellada; Font Mireia; Emili Fernandez-Egea; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo
Journal:  Psychopharmacology (Berl)       Date:  2006-09-22       Impact factor: 4.530

2.  Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism.

Authors:  Jose J Mateos; Francisco Lomeña; Eduardo Parellada; Mireia Font; Emili Fernandez; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

Review 3.  Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations.

Authors:  M R Caligiuri; D V Jeste; J P Lacro
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 4.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

5.  Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.

Authors:  Michele Tinazzi; Angelo Antonini; Tommaso Bovi; Isabella Pasquin; Maria Steinmayr; Giuseppe Moretto; Antonio Fiaschi; Sarah Ottaviani
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

6.  Parkinsonism and tremor disorders. A clinical approach.

Authors:  Hani Ts Benamer
Journal:  Libyan J Med       Date:  2007-06-01       Impact factor: 1.657

7.  Drug-induced parkinsonism.

Authors:  Hae-Won Shin; Sun Ju Chung
Journal:  J Clin Neurol       Date:  2012-03-31       Impact factor: 3.077

8.  Clinical Spectrum of Drug-Induced Movement Disorders: A Study of 97 Patients.

Authors:  Anjali Chouksey; Sanjay Pandey
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2020-10-26

Review 9.  Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism.

Authors:  Elena E Vaiman; Natalia A Shnayder; Aiperi K Khasanova; Anna I Strelnik; Arseny J Gayduk; Mustafa Al-Zamil; Margarita R Sapronova; Natalia G Zhukova; Daria A Smirnova; Regina F Nasyrova
Journal:  Biomedicines       Date:  2022-08-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.